Condition: Advanced Solid Tumor · Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd.
A Phase 1 First-in-Human study of YL217 in Patients with Advanced Solid Tumors
This description comes directly from the study's public registry record.
Angie Cao, MD · +86 0512-62858368 · clinicaltrials@medilinkthera.com
Always discuss trial participation with your own doctor first.
| Mayo Clinic Arizona | Phoenix, Arizona, United States | Recruiting |
| UCLA Hematology/Oncology - Santa Monica | Santa Monica, California, United States | Recruiting |
| Yale Cancer Center | New Haven, Connecticut, United States | Recruiting |
| The University of Kansas Cancer Center (KUCC) | Kansas City, Kansas, United States | Recruiting |
| University of Maryland Medical Center-Greenebaum Cancer Ctr - Medical Oncology | Baltimore, Maryland, United States | Not Yet Recruiting |
| Karmanos Cancer Institute | Detroit, Michigan, United States | Recruiting |
| Columbia University Irving Medical Center | New York, New York, United States | Recruiting |
| Duke University Medical Center (DUMC) | Durham, North Carolina, United States | Recruiting |
| University of Cincinnati Medical Center | Cincinnati, Ohio, United States | Recruiting |
| Cleveland Clinic Taussig Cancer Institute | Cleveland, Ohio, United States | Recruiting |
| The University of Texas MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
| UT Health San Antonio - Mays Cancer Center | San Antonio, Texas, United States | Recruiting |
+ 7 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06859762